A New Era of Cancer Therapy Has Begun – PD-1:VEGF BsAbs
In recent years, immune checkpoint inhibitors have dominated the healthcare landscape. In fact, last year, Merck's PD-1 mAb KEYTRUDA was the most successful drug in all of medicine. However, a new wave of medicine is on the horizon that is threatening to topple Merck's oncology kingdom and usurp KEYTRUDA's throne. Multi-specific protein therapeutics - bispecific antibodies being the most popular.
